Last reviewed · How we verify
INV-102
At a glance
| Generic name | INV-102 |
|---|---|
| Sponsor | Invirsa, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy (PHASE2)
- Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis (PHASE2)
- Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease (PHASE2)
- Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INV-102 CI brief — competitive landscape report
- INV-102 updates RSS · CI watch RSS
- Invirsa, Inc. portfolio CI